SAN DIEGO, Sept. 30 /PRNewswire/ -- Researchers at the National Institute on Aging, Baltimore, MD,
and Massachusetts General Hospital, Boston, today reported a potent, enhanced insulin response
following exendin-4 administration in a study of people with type 2 diabetes. The results of the study
were presented today by Josephine M. Egan, MD from the National Institute on Aging at the 35th Annual
Meeting of the European Association for the Study of Diabetes currently taking place in Brussels,
Belgium.
These independent researchers examined the effects of intravenous infusion of exendin-4 in people with
type 2 diabetes and in those who do not have diabetes. Subjects were studied during a period of
continued high blood glucose concentrations, followed by a meal. The researchers reported that
exendin-4 administration resulted in a sustained, enhanced insulin response during the high blood
glucose period in both groups of subjects studied. In addition, no increase in blood glucose was
observed following the meal, which was given three and one-half hours after the exendin-4 infusion was
stopped.
"These results provide further confirmation in humans of previously reported results from studies of
exendin-4 in animals that demonstrated enhanced insulin secretion in response to elevated blood
glucose," commented Orville G. Kolterman, MD, Senior Vice President, Clinical Affairs at Amylin
Pharmaceuticals (Nasdaq: AMLN). "These data are supportive of our AC2993 (synthetic exendin-4)
Phase 2 development program for treatment of type 2 diabetes." |
